Skip to main content
Premium Trial:

Request an Annual Quote

Syrrx Locks Onto $18.5M in Additional Private Equity

SAN FRANCISCO, Dec. 26 - Structural genomics company Syrrx said on Wednesday it received $18.5 million in its latest round of private equity funding.


The investment, led by Zurich, Switzerland-based HBM Partners, brings to $98.5 million Syrxx's total equity-investment pot, according to the company.


"Along with the $20 million debt financing arranged for our new facility earlier this year, this round of financing will assure investors that our operating funds will allow for the completion of our strategic plan through 2004," Norman Halleen, CFO of Syrrx, said in a statement.


Two weeks ago, Syrrx, based in San Diego, announced a research collaboration with Celera Genomics  under which Syrrx will receive a series of R&D payments to determine the three-dimensional structures of proteins identified by Celera as potential drug targets.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.